How the FDA is Shaping the Future of Cell and Gene Therapies: A Fireside Chat with Dr. Peter Marks

A new generation of cell therapies and genetic medicines is transforming the way we treat—and potentially cure—various diseases. As these therapies advance and impact patients' lives, hurdles around reimbursement and access still persist.

During Advanced Therapies: Cell & Gene, mRNA and Beyond, a complimentary virtual event taking place on November 20th, we will discuss today's challenges and what the future holds for potentially lifesaving gene editing tools and cell therapies.

Register today to secure your spot and hear from expert leaders.

Fireside Chat: What's Beyond Cell & Gene Therapies

More cell and gene therapies are coming, raising unique challenges for drug developers and regulators. In this conversation with Dr. Peter Marks, director of FDA’s CBER, we will discuss how the FDA is adapting to new cell and gene therapy technologies, the development of new regulatory tools, and the careful balance between benefit and risk.   

Angus Liu
Deputy Editor

Fierce Pharma

Peter Marks, M.D., Ph.D.
Director of the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration

• Cell & Gene Therapy Manufacturing: A Look at Supply Chains, Treatment Centers and Patient Slots
• Accelerating Genetic Medicines: Innovations in Biomanufacturing for Cell and Gene Therapy
• Cell & Gene Therapy Pulse Check: Overcoming Infrastructure and Payer Concerns
• Harnessing In Vivo Gene Editing: Breakthroughs and Applications
• Transforming Patient Care by Meeting the Challenges of CGT 

If you no longer wish to receive promotion on this event, simply unsubscribe.
Refer to our Privacy Policy.

Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017

Contact Us
© 2024 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.